Dexco Statistics
Total Valuation
Dexco has a market cap or net worth of BRL 4.31 billion. The enterprise value is 10.41 billion.
Important Dates
The last earnings date was Wednesday, November 4, 2026.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Dexco has 907.87 million shares outstanding. The number of shares has increased by 0.87% in one year.
| Current Share Class | 907.87M |
| Shares Outstanding | 907.87M |
| Shares Change (YoY) | +0.87% |
| Shares Change (QoQ) | +0.38% |
| Owned by Insiders (%) | 19.49% |
| Owned by Institutions (%) | 29.74% |
| Float | 279.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 8.01 |
| PS Ratio | 0.51 |
| PB Ratio | 0.65 |
| P/TBV Ratio | 0.73 |
| P/FCF Ratio | 5.00 |
| P/OCF Ratio | 2.36 |
| PEG Ratio | 0.06 |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 4.92, with an EV/FCF ratio of 11.88.
| EV / Earnings | n/a |
| EV / Sales | 1.21 |
| EV / EBITDA | 4.92 |
| EV / EBIT | 13.15 |
| EV / FCF | 11.88 |
Financial Position
The company has a current ratio of 2.00, with a Debt / Equity ratio of 1.24.
| Current Ratio | 2.00 |
| Quick Ratio | 1.46 |
| Debt / Equity | 1.24 |
| Debt / EBITDA | 4.47 |
| Debt / FCF | 10.21 |
| Interest Coverage | 0.62 |
Financial Efficiency
Return on equity (ROE) is -1.45% and return on invested capital (ROIC) is 5.19%.
| Return on Equity (ROE) | -1.45% |
| Return on Assets (ROA) | 2.31% |
| Return on Invested Capital (ROIC) | 5.19% |
| Return on Capital Employed (ROCE) | 4.33% |
| Weighted Average Cost of Capital (WACC) | 8.84% |
| Revenue Per Employee | 610,242 |
| Profits Per Employee | -14,688 |
| Employee Count | 13,344 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 3.67 |
Taxes
| Income Tax | -139.45M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.54% in the last 52 weeks. The beta is 0.51, so Dexco's price volatility has been lower than the market average.
| Beta (5Y) | 0.51 |
| 52-Week Price Change | -0.54% |
| 50-Day Moving Average | 5.89 |
| 200-Day Moving Average | 5.30 |
| Relative Strength Index (RSI) | 38.68 |
| Average Volume (20 Days) | 5,410,590 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Dexco had revenue of BRL 8.68 billion and -208.98 million in losses. Loss per share was -0.23.
| Revenue | 8.68B |
| Gross Profit | 2.13B |
| Operating Income | 688.23M |
| Pretax Income | -243.16M |
| Net Income | -208.98M |
| EBITDA | 1.98B |
| EBIT | 688.23M |
| Loss Per Share | -0.23 |
Full Income Statement Balance Sheet
The company has 3.42 billion in cash and investments and 9.04 billion in debt, with a net cash position of -5.62 billion or -6.19 per share.
| Cash & Investments | 3.42B |
| Total Debt | 9.04B |
| Net Cash | -5.62B |
| Net Cash Per Share | -6.19 |
| Equity (Book Value) | 7.29B |
| Book Value Per Share | 7.50 |
| Working Capital | 3.35B |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was 1.88 billion and capital expenditures -991.92 million, giving a free cash flow of 885.12 million.
| Operating Cash Flow | 1.88B |
| Capital Expenditures | -991.92M |
| Depreciation & Amortization | 1.29B |
| Net Borrowing | 466.88M |
| Free Cash Flow | 885.12M |
| FCF Per Share | 0.97 |
Full Cash Flow Statement Margins
Gross margin is 24.48%, with operating and profit margins of 7.93% and -2.41%.
| Gross Margin | 24.48% |
| Operating Margin | 7.93% |
| Pretax Margin | -2.80% |
| Profit Margin | -2.41% |
| EBITDA Margin | 22.80% |
| EBIT Margin | 7.93% |
| FCF Margin | 10.19% |
Dividends & Yields
This stock pays an annual dividend of 0.19, which amounts to a dividend yield of 4.05%.
| Dividend Per Share | 0.19 |
| Dividend Yield | 4.05% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.87% |
| Shareholder Yield | 3.08% |
| Earnings Yield | -4.80% |
| FCF Yield | 20.02% |
Dividend Details Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Analyst Forecast
The average price target for Dexco is 8.13, which is 71.16% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 8.13 |
| Price Target Difference | 71.16% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 4.68% |
| EPS Growth Forecast (3Y) | 61.32% |
Stock Splits
The last stock split was on December 26, 2025. It was a forward split with a ratio of 1.12.
| Last Split Date | Dec 26, 2025 |
| Split Type | Forward |
| Split Ratio | 1.12 |
Scores
Dexco has an Altman Z-Score of 1.1 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.1 |
| Piotroski F-Score | 6 |